MAIA Biotechnology (MAIA) vs Rafael (RFL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rafael (RFL) has outperformed MAIA Biotechnology (MAIA) over the past year, gaining 9.6% versus a loss of 36.5%. Rafael is the larger company by market cap ($82.2 million vs $75.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MAIA | RFL |
|---|---|---|
| Share price | $1.22 | $1.58 |
| Market cap | $75.02M | $82.16M |
| 1-day change | +5.68% | +6.76% |
| YTD return | -24.84% | +25.42% |
| 1-year return | -36.46% | +9.63% |
| 5-year return | — | -95.09% |
| Forward P/E | 1.09 | — |
| EPS (TTM) | $-0.62 | $-0.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.19 | $3.96 |
| 52-week low | $0.87 | $1.12 |
| Distance from 52-week high | -61.91% | -60.10% |
| Analyst consensus | none | — |
| Avg. price target upside | +887.65% | — |
| Average volume | 527.89K | 159.84K |
| Shares outstanding | 61.74M | 51.21M |
| Employees | 13 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RFL has outperformed MAIA by 46.1 percentage points over the past year.
About MAIA Biotechnology
MAIA stock →MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About Rafael
RFL stock →Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
MAIA vs RFL FAQ
Which is bigger, MAIA Biotechnology or Rafael?
Rafael (RFL) is larger, with a market capitalization of $82.16M compared with $75.02M for MAIA Biotechnology (MAIA).
Which stock has performed better over the past year, MAIA or RFL?
RFL returned +9.63% over the past 12 months, compared with -36.46% for MAIA (price return, excluding dividends). Past performance does not predict future results.
Are MAIA Biotechnology and Rafael in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.